Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Volrustomig with or without Casdatifan against Nivolumab plus Ipilimumab as first-line treatment for advanced clear cell renal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Casdatifan
• Volrustomig
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING